Like other topical corticosteroids Clobetasol Propionate Lotion 0.05% has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids in general is unclear. However, corticosteroids are thought to act by induction of phospholipase A inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A .

Clobetasol Propionate Lotion, 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, in patients 18 years of age or older. Limitations of Use:

• Do not use on the face, axillae or groin. 
• Do not use if atrophy is present at the treatment site. 
• Do not use for rosacea or perioral dermatitis. 

• Not for oral, ophthalmic, or intravaginal use.
• Clobetasol Propionate Lotion 0.05% should be applied directly onto the affected skin areas twice daily and rubbed in gently.
• Clobetasol Propionate Lotion 0.05% contains a super-high potent topical corticosteroid; therefore treatment should be limited to 2 weeks. For moderate to severe plaque psoriasis, treatment may be extended for additional 2 weeks for localized lesions (<10% body surface area) that have not sufficiently improved.
• Total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week.

The most common adverse reactions (incidence > 1%) are skin atrophy, telangiectasia, discomfort skin and skin dry.

None.

Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the hypothalamic-pituitaryadrenal (HPA) axis at the lowest doses tested. 

Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.

Systemic absorption may require periodic evaluation for HPA axis suppression. Modify use if HPA axis suppression develops.

Children may be more susceptible to systemic toxicity from use of topical corticosteroids. 

Local adverse reactions with topical corticosteroids may occur more frequently with the use of occlusive dressings and higher potency corticosteroids, including clobetasol propionate. These reactions include: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae and miliaria.